NASDAQ · ADILHealthcarePharmaceuticals

Adial Pharmaceuticals financials

$4.15+2.72%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
Revenue$0.00$0.00$0.00$0.00————
Gross profit$0.00$0.00$0.00$0.00———-$1.2M
Gross margin————————
Operating income-$7.8M-$8.3M-$6.9M-$10.9M-$19.3M-$10.9M-$8.2M-$8.2M
Net income-$8.0M-$13.2M-$5.1M-$12.7M-$19.4M-$10.9M-$8.6M-$11.6M
Net margin————————
Diluted EPS$-11.93$-68.01$-90.00$-317.75$-650.00$-543.75$-543.75$-1525.00
EBITDA-$7.8M-$8.3M-$6.9M-$10.9M-$17.7M-$10.9M-$8.2M-$8.2M
Operating cash flow-$6.5M-$6.9M-$6.8M-$11.2M-$11.9M-$7.6M-$6.3M-$2.5M
Free cash flow-$6.5M-$6.9M-$6.8M-$11.2M-$12.0M-$7.6M——
Diluted shares0.7M0.2M0.1M0.0M0.0M0.0M0.0M0.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$5.9M$3.8M$2.8M$4.0M$6.1M$4.4M
Short-term investments$0.00$0.00$0.00$0.00——
Total debt$0.00$0.00$0.00$0.00$1.1M$0.00
Total assets$6.7M$5.0M$4.7M$5.7M$7.5M$5.5M
Total liabilities$1.4M$975.9K$653.1K$2.5M$4.0M$1.5M
Shareholders' equity$5.3M$4.1M$4.1M$3.3M$3.5M$4.0M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology